Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8546399 | ABBVIE INC | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Jun, 2031
(7 years from now) | |
US10730873 | ABBVIE INC | Salts and crystalline forms of an apoptosis-inducing agent |
Nov, 2031
(7 years from now) | |
US8722657 | ABBVIE INC | Salts and crystalline forms of an apoptosis-inducing agent |
Jan, 2032
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9174982 | ABBVIE INC | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
May, 2030
(6 years from now) | |
US11369599 | ABBVIE INC | Melt-extruded solid dispersions containing an apoptosis-inducing agent |
May, 2032
(8 years from now) | |
US10993942 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
US11110087 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(9 years from now) | |
US11413282 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
US9539251 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | May 15, 2026 |
Market Authorisation Date: 11 April, 2016
Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll); Treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnos...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11590128 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | May 15, 2026 |
Market Authorisation Date: 11 April, 2016
Treatment: Treatment of aml by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine to adults 75 years or older or having certain comorbidities per a dose ramp-up including an in...
Dosage: TABLET;ORAL